Cargando…
The Mortality Risk and Pulmonary Fibrosis Investigated by Time-Resolved Fluorescence Spectroscopy from Plasma in COVID-19 Patients
A method of rapidly pointing out the risk of developing persistent pulmonary fibrosis from a sample of blood is extraordinarily needed for diagnosis, prediction of death, and post-infection prognosis assessment. Collagen scar formation has been found to play an important role in the lung remodeling...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457233/ https://www.ncbi.nlm.nih.gov/pubmed/36079011 http://dx.doi.org/10.3390/jcm11175081 |
_version_ | 1784786005451079680 |
---|---|
author | Wybranowski, Tomasz Pyskir, Jerzy Bosek, Maciej Napiórkowska, Marta Cyrankiewicz, Michał Ziomkowska, Blanka Pilaczyńska-Cemel, Marta Pyskir, Małgorzata Rogańska, Milena Kruszewski, Stefan Przybylski, Grzegorz |
author_facet | Wybranowski, Tomasz Pyskir, Jerzy Bosek, Maciej Napiórkowska, Marta Cyrankiewicz, Michał Ziomkowska, Blanka Pilaczyńska-Cemel, Marta Pyskir, Małgorzata Rogańska, Milena Kruszewski, Stefan Przybylski, Grzegorz |
author_sort | Wybranowski, Tomasz |
collection | PubMed |
description | A method of rapidly pointing out the risk of developing persistent pulmonary fibrosis from a sample of blood is extraordinarily needed for diagnosis, prediction of death, and post-infection prognosis assessment. Collagen scar formation has been found to play an important role in the lung remodeling following SARS-CoV-2 infection. For this reason, the concentration of collagen degradation products in plasma may reflect the process of lung remodeling and determine the extent of fibrosis. According to our previously published results of an in vitro study, an increase in the concentration of type III collagen degradation products in plasma resulted in a decrease in the fluorescence lifetime of plasma at a wavelength of 450 nm. The aim of this study was to use time-resolved fluorescence spectroscopy to assess pulmonary fibrosis, and to find out if the lifetime of plasma fluorescence is shortened in patients with COVID-19. The presented study is thus far the only one to explore the fluorescence lifetime of plasma in patients with COVID-19 and pulmonary fibrosis. The time-resolved spectrometer Life Spec II with the sub-nanosecond pulsed 360 nm EPLED® diode was used in order to measure the fluorescence lifetime of plasma. The survival analysis showed that COVID-19 mortality was associated with a decreased mean fluorescence lifetime of plasma. The AUC of mean fluorescence lifetime in predicting death was 0.853 (95% CI 0.735–0.972, p < 0.001) with a cut-off value of 7 ns, and with 62% sensitivity and 100% specificity. We observed a significant decrease in the mean fluorescence lifetime in COVID-19 non-survivors (p < 0.001), in bacterial pneumonia patients without COVID-19 (p < 0.001), and in patients diagnosed with idiopathic pulmonary fibrosis (p < 0.001), relative to healthy subjects. Furthermore, these results suggest that the development of pulmonary fibrosis may be a real and serious problem in former COVID-19 patients in the future. A reduction in the mean fluorescence lifetime of plasma was observed in many patients 6 months after discharge. On the basis of these data, it can be concluded that a decrease in the mean fluorescence lifetime of plasma at 450 nm may be a risk factor for mortality, and probably also for pulmonary fibrosis in hospitalized COVID-19 patients. |
format | Online Article Text |
id | pubmed-9457233 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94572332022-09-09 The Mortality Risk and Pulmonary Fibrosis Investigated by Time-Resolved Fluorescence Spectroscopy from Plasma in COVID-19 Patients Wybranowski, Tomasz Pyskir, Jerzy Bosek, Maciej Napiórkowska, Marta Cyrankiewicz, Michał Ziomkowska, Blanka Pilaczyńska-Cemel, Marta Pyskir, Małgorzata Rogańska, Milena Kruszewski, Stefan Przybylski, Grzegorz J Clin Med Article A method of rapidly pointing out the risk of developing persistent pulmonary fibrosis from a sample of blood is extraordinarily needed for diagnosis, prediction of death, and post-infection prognosis assessment. Collagen scar formation has been found to play an important role in the lung remodeling following SARS-CoV-2 infection. For this reason, the concentration of collagen degradation products in plasma may reflect the process of lung remodeling and determine the extent of fibrosis. According to our previously published results of an in vitro study, an increase in the concentration of type III collagen degradation products in plasma resulted in a decrease in the fluorescence lifetime of plasma at a wavelength of 450 nm. The aim of this study was to use time-resolved fluorescence spectroscopy to assess pulmonary fibrosis, and to find out if the lifetime of plasma fluorescence is shortened in patients with COVID-19. The presented study is thus far the only one to explore the fluorescence lifetime of plasma in patients with COVID-19 and pulmonary fibrosis. The time-resolved spectrometer Life Spec II with the sub-nanosecond pulsed 360 nm EPLED® diode was used in order to measure the fluorescence lifetime of plasma. The survival analysis showed that COVID-19 mortality was associated with a decreased mean fluorescence lifetime of plasma. The AUC of mean fluorescence lifetime in predicting death was 0.853 (95% CI 0.735–0.972, p < 0.001) with a cut-off value of 7 ns, and with 62% sensitivity and 100% specificity. We observed a significant decrease in the mean fluorescence lifetime in COVID-19 non-survivors (p < 0.001), in bacterial pneumonia patients without COVID-19 (p < 0.001), and in patients diagnosed with idiopathic pulmonary fibrosis (p < 0.001), relative to healthy subjects. Furthermore, these results suggest that the development of pulmonary fibrosis may be a real and serious problem in former COVID-19 patients in the future. A reduction in the mean fluorescence lifetime of plasma was observed in many patients 6 months after discharge. On the basis of these data, it can be concluded that a decrease in the mean fluorescence lifetime of plasma at 450 nm may be a risk factor for mortality, and probably also for pulmonary fibrosis in hospitalized COVID-19 patients. MDPI 2022-08-30 /pmc/articles/PMC9457233/ /pubmed/36079011 http://dx.doi.org/10.3390/jcm11175081 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wybranowski, Tomasz Pyskir, Jerzy Bosek, Maciej Napiórkowska, Marta Cyrankiewicz, Michał Ziomkowska, Blanka Pilaczyńska-Cemel, Marta Pyskir, Małgorzata Rogańska, Milena Kruszewski, Stefan Przybylski, Grzegorz The Mortality Risk and Pulmonary Fibrosis Investigated by Time-Resolved Fluorescence Spectroscopy from Plasma in COVID-19 Patients |
title | The Mortality Risk and Pulmonary Fibrosis Investigated by Time-Resolved Fluorescence Spectroscopy from Plasma in COVID-19 Patients |
title_full | The Mortality Risk and Pulmonary Fibrosis Investigated by Time-Resolved Fluorescence Spectroscopy from Plasma in COVID-19 Patients |
title_fullStr | The Mortality Risk and Pulmonary Fibrosis Investigated by Time-Resolved Fluorescence Spectroscopy from Plasma in COVID-19 Patients |
title_full_unstemmed | The Mortality Risk and Pulmonary Fibrosis Investigated by Time-Resolved Fluorescence Spectroscopy from Plasma in COVID-19 Patients |
title_short | The Mortality Risk and Pulmonary Fibrosis Investigated by Time-Resolved Fluorescence Spectroscopy from Plasma in COVID-19 Patients |
title_sort | mortality risk and pulmonary fibrosis investigated by time-resolved fluorescence spectroscopy from plasma in covid-19 patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457233/ https://www.ncbi.nlm.nih.gov/pubmed/36079011 http://dx.doi.org/10.3390/jcm11175081 |
work_keys_str_mv | AT wybranowskitomasz themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT pyskirjerzy themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT bosekmaciej themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT napiorkowskamarta themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT cyrankiewiczmichał themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT ziomkowskablanka themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT pilaczynskacemelmarta themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT pyskirmałgorzata themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT roganskamilena themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT kruszewskistefan themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT przybylskigrzegorz themortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT wybranowskitomasz mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT pyskirjerzy mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT bosekmaciej mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT napiorkowskamarta mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT cyrankiewiczmichał mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT ziomkowskablanka mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT pilaczynskacemelmarta mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT pyskirmałgorzata mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT roganskamilena mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT kruszewskistefan mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients AT przybylskigrzegorz mortalityriskandpulmonaryfibrosisinvestigatedbytimeresolvedfluorescencespectroscopyfromplasmaincovid19patients |